Neurobiology of Aging
Volume 29, Issue 8 , Pages 1204-1217 , August 2008

PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD

  • A. Kadir

      Affiliations

    • Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • ,
  • T. Darreh-Shori

      Affiliations

    • Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • ,
  • O. Almkvist

      Affiliations

    • Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • Department of Psychology, Stockholm University, Sweden
    • ,
  • A. Wall

      Affiliations

    • Uppsala PET Centre/Uppsala Imanet, Uppsala, Sweden
    • ,
  • M. Grut

      Affiliations

    • Geriatrics Clinic, Danderyd Hospital, Stockholm, Sweden
    • ,
  • B. Strandberg

      Affiliations

    • Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • ,
  • A. Ringheim

      Affiliations

    • Uppsala PET Centre/Uppsala Imanet, Uppsala, Sweden
    • ,
  • B. Eriksson

      Affiliations

    • Janssen-Cilag, Sollentuna, Sweden
    • ,
  • G. Blomquist

      Affiliations

    • Uppsala PET Centre/Uppsala Imanet, Uppsala, Sweden
    • Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Sweden
    • ,
  • B. Långström

      Affiliations

    • Uppsala PET Centre/Uppsala Imanet, Uppsala, Sweden
    • ,
  • A. Nordberg

      Affiliations

    • Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • Corresponding Author InformationCorresponding author at: Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Molecular Neuropharmacology, Karolinska University Hospital Huddinge, Novum Floor-5, S-141 86 Stockholm, Sweden. Tel.: +46 8 585 854 67; fax: +46 8 585 854 70.

Received 24 October 2006 ,Revised 18 January 2007 ,Accepted 14 February 2007.

References 

  1. Alhainen K, Helkala EL, Riekkinen P. Psychometric discrimination of tetrahydroaminoacridine responders in Alzheimer patients. Dementia. 1993;4(1):54–58
  2. Almkvist O, Darreh-Shori T, Stefanova E, Spiegel R, Nordberg A. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients. Eur. J. Neurol. 2004;11(4):253–261
  3. Almkvist O, Jelic V, Amberla K, Hellstrom-Lindahl E, Meurling L, Nordberg A. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Dement. Geriatr. Cogn. Disord. 2001;12(1):22–32
  4. Anderson J. A rapid and accurate method to realign PET-scans utilizing image edge information. J. Nucl. Med. 1995;36:657–669
  5. Backman L, Forsell Y. Episodic memory functioning in a community-based sample of old adults with major depression: utilization of cognitive support. J. Abnorm. Psychol. 1994;103(2):361–370
  6. Blomqvist G. On the construction of functional maps in positron emission tomography. J. Cereb. Blood Flow Metab. 1984;4(4):629–632
  7. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti B, Davis JG, et al. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. Neurosci. Lett. 2005;380(1–2):127–132
  8. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Koeppe RA, et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 2005;76(3):315–319
  9. Bores GM, Huger FP, Petko W, Mutlib AE, Camacho F, Rush DK, et al. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J. Pharmacol. Exp. Ther. 1996;277(2):728–738
  10. Cabeza R, Nyberg L. Imaging cognition. II. An empirical review of 275 PET and fMRI studies. J. Cogn. Neurosci. 2000;12(1):1–47
  11. Cahn-Weiner DA, Sullivan EV, Shear PK, Fama R, Lim KO, Yesavage JA, et al. Brain structural and cognitive correlates of clock drawing performance in Alzheimer's disease. J. Int. Neuropsychol. Soc. 1999;5(6):502–509
  12. Darreh-Shori T, Almkvist O, Guan ZZ, Garlind A, Strandberg B, Svensson AL, et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology. 2002;59(4):563–572
  13. Darreh-Shori T, Kadir A, Almkvist O, Grut M, Wall A, Blomquist G, et al. Inhibition of acetylcholinesterase in CSF versus brain assessed by (11)C-PMP PET in AD patients treated with galantamine. Neurobiol Aging. 2008;29:168–184
  14. Darreh-Shori T, Meurling L, Pettersson T, Hugosson K, Hellstrom-Lindahl E, Andreasen N, et al. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. J. Neural. Transm. 2006;113(11):1791–1801
  15. Ding YS, Fowler JS, Logan J, Wang GJ, Telang F, Garza V, et al. 6-[18F]Fluoro-A-85380, a new PET tracer for the nicotinic acetylcholine receptor: studies in the human brain and in vivo demonstration of specific binding in white matter. Synapse. 2004;53(3):184–189
  16. Ellis JR, Villemagne VL, Nathan PJ, Mulligan RS, Gong SJ, Smith CL, et al. Nicotinic receptor upregulation and the cognitive effects of galantamine in Alzheimer's disease: a human in vivo study using [18F]F-A-85380 PET. Alzheimers Dement. 2006;2(3):S353–S354
  17. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975;12(3):189–198
  18. Gallezot JD, Bottlaender M, Gregoire MC, Roumenov D, Deverre JR, Coulon C, et al. In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET. J. Nucl. Med. 2005;46(2):240–247
  19. Geerts H, Finkel L, Carr R, Spiros A. Nicotinic receptor modulation: advantages for successful Alzheimer's disease therapy. J. Neural. Transm. Suppl. 2002;(62):203–216
  20. Gundisch D, Koren AO, Horti AG, Pavlova OA, Kimes AS, Mukhin AG, et al. In vitro characterization of 6-[18F]fluoro-A-85380, a high-affinity ligand for alpha4beta2* nicotinic acetylcholine receptors. Synapse. 2005;55(2):89–97
  21. Herscovitch P, Markham J, Raichle ME. Brain blood flow measured with intravenous H2(15)O. I. Theory and error analysis. J. Nucl. Med. 1983;24(9):782–789
  22. Iyo M, Namba H, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, et al. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet. 1997;349(9068):1805–1809
  23. Kaasinen V, Nagren K, Jarvenpaa T, Roivainen A, Yu M, Oikonen V, et al. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J. Clin. Psychopharmacol. 2002;22(6):615–620
  24. Kadir A, Almkvist O, Wall A, Langstrom B, Nordberg A. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology. 2006;188(4):509–520
  25. Koeppe RA, Frey KA, Snyder SE, Meyer P, Kilbourn MR, Kuhl DE. Kinetic modeling of N-[11C]methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography trace for measurement of acetylcholinesterase activity in human brain. J. Cereb. Blood Flow Metab. 1999;19(10):1150–1163
  26. Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology. 1999;52(4):691–699
  27. Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann. Neurol. 2000;48(3):391–395
  28. Kadir, A., Darreh-Shori, T., Almkvist, O., Wall, A., Långström, B., Nordberg, A., 2007. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. Psychopharmacology, doi:10.1007/s00213-007-0725-z.
  29. Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr. Drug Targets CNS Neurol. Disord. 2002;1(4):423–431
  30. Lezak M. Neuropsychological Assessment. 3rd ed.. New York: Oxford University Press; 1995;
  31. Lundqvist H, Nordberg A, Hartvig P, Langstrom B. (S)-(−)-[11C]Nicotine binding assessed by PET: a dual tracer model evaluated in the rhesus monkey brain. Alzheimer Dis. Assoc. Disord. 1998;12(3):238–246
  32. Luria A. Higher Cortical Functions in Man. New York: Basic Books; 1966;
  33. Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol. Psychiatry. 2001;49(3):279–288
  34. Maziere M, Comar D, Maranzo C, Berger G. Nicotine-11C: synthesis and distribution kinetics in animals. Eur. J. Nucl. Med. 1976;1:255–258
  35. Maziere M, Delforge J. PET imaging [11C]nicotine: historical aspects. In:  Domino E editors. Brain Imaging of Nicotine and Tobacco Smoking. Ann Arbor: NPP Books; 1995;p. 13–28
  36. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939–944
  37. Mogg AJ, Jones FA, Pullar IA, Sharples CG, Wonnacott S. Functional responses and subunit composition of presynaptic nicotinic receptor subtypes explored using the novel agonist 5-iodo-A-85380. Neuropharmacology. 2004;47(6):848–859
  38. Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol. Bull. 1983;19(3):448–450
  39. Mousavi M, Bednar I, Nordberg A. Selective changes in expression of different nicotinic receptor subtypes in brain and adrenal glands of mice carrying human mutated gene for APP or over-expressing human acetylcholinestrase. Int. J. Dev. Neurosci. 2004;22(7):545–549
  40. Nordberg A. Visualization of nicotinic and muscarinic receptors in brain by positron emission tomography. In:  Giacobini E,  Pepeu G editor. The Brain Cholinergic System in Health and Disease. London: Informa Healthcare; 2006;p. 181–190
  41. Nordberg A, Amberla K, Shigeta M, Lundqvist H, Viitanen M, Hellstrom-Lindahl E, et al. Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. Alzheimer Dis. Assoc. Disord. 1998;12(3):228–237
  42. Nordberg A, Hartvig P, Lilja A, Viitanen M, Amberla K, Lundqvist H, et al. Decreased uptake and binding of 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography. J. Neural. Transm. Park Dis. Dement. Sect. 1990;2(3):215–224
  43. Nordberg A, Lilja A, Lundqvist H, Hartvig P, Amberla K, Viitanen M, et al Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol. Aging. 1992;13(6):747–758
  44. Nordberg A, Lundqvist H, Hartvig P, Andersson J, Johansson M, Hellstrom-Lindahi E, et al. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. Dement. Geriatr. Cogn. Disord. 1997;8(2):78–84
  45. Nordberg A, Lundqvist H, Hartvig P, Lilja A, Langstrom B. Kinetic analysis of regional (S)(−)11C-nicotine binding in normal and Alzheimer brains—in vivo assessment using positron emission tomography. Alzheimer Dis. Assoc. Disord. 1995;9(1):21–27
  46. Raichle ME, Martin WR, Herscovitch P, Mintun MA, Markham J. Brain blood flow measured with intravenous H2(15)O. II. Implementation and validation. J. Nucl. Med. 1983;24(9):790–798
  47. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch. Neurol. 2004;61(2):252–256
  48. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000;54(12):2261–2268
  49. Ringman JM, Cummings JL. Current and emerging pharmacological treatment options for dementia. Behav. Neurol. 2006;17(1):5–16
  50. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999;318(7184):633–638
  51. Sahakian BJ, Owen AM, Morant NJ, Eagger SA, Boddington S, Crayton L, et al. Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology (Berlin). 1993;110(4):395–401
  52. Samochocki M, Zerlin M, Jostock R, Groot Kormelink PJ, Luyten WH, Albuquerque EX, et al. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol. Scand. Suppl. 2000;176:68–73
  53. Shinotoh H, Aotsuka A, Fukushi K, Nagatsuka S, Tanaka N, Ota T, et al. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology. 2001;56(3):408–410
  54. Snyder SE, Tluczek L, Jewett DM, Nguyen TB, Kuhl DE, Kilbourn MR. Synthesis of 1-[11C]methylpiperidin-4-yl propionate ([11C]PMP) for in vivo measurements of acetylcholinesterase activity. Nucl. Med. Biol. 1998;25(8):751–754
  55. Svedberg MM, Svensson AL, Bednar I, Nordberg A. Neuronal nicotinic and muscarinic receptor subtypes at different ages of transgenic mice overexpressing human acetylcholinesterase. Neurosci. Lett. 2003;340(2):148–152
  56. Svedberg MM, Svensson AL, Johnson M, Lee M, Cohen O, Court J, et al. Upregulation of neuronal nicotinic receptor subunits alpha4, beta2, and alpha7 in transgenic mice overexpressing human acetylcholinesterase. J. Mol. Neurosci. 2002;18(3):211–222
  57. Svensson AL, Nordberg A. Interaction of tacrine, galanthamine, NXX-066, and E2020 with neuronal a4β2 nicotinic receptors expressed in fibroblast cells. In:  Iqbal K,  Winblad B,  Nishimura T,  Takeda M,  Wisniewski HM editor. Alzheimer's Disease Biology, Diagnosis and Therapeutics. Chichester: John Whiley & Sons; 1997;p. 751–756
  58. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000;54(12):2269–2276
  59. Vellas B, Cunha L, Gertz HJ, De Deyn PP, Wesnes K, Hammond G, et al. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. Curr. Med. Res. Opin. 2005;21(9):1423–1429
  60. Voytko ML, Olton DS, Richardson RT, Gorman LK, Tobin JR, Price DL. Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J. Neurosci. 1994;14(1):167–186
  61. Watson CCND, Casey ME, et al. Evaluation of simulation based scatter correction for 3D PET cardiac imaging. IEEE Trans. Nucl. Sci. 1997;21:136–144
  62. Wechsler D. Wechsler Adult Intelligence Scale—Revised Manual. New York: Psychological Corporation; 1981;
  63. Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int. J. Geriatr. Psychiatry. 2004;19(7):624–633
  64. Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging. 2003;20(10):777–789
  65. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57(3):489–495
  66. Woodruff-Pak DS, Lander C, Geerts H. Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002;8(4):405–426

PII: S0197-4580(07)00058-9

doi: 10.1016/j.neurobiolaging.2007.02.020

Neurobiology of Aging
Volume 29, Issue 8 , Pages 1204-1217 , August 2008

Article Tools

* Image Usage & Resolution